These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2092121)

  • 1. CAM 26 and CAM 29: methodological evaluations and first clinical employment in breast cancer.
    Priolo G; Pecchio F; Rapellino M; Aimo G; Spertino F; Pepe C
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):21-3. PubMed ID: 2092121
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tumor markers in the diagnosis and prognosis of breast cancer].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
    Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical usefulness of CA M26 and CA M29 in breast carcinoma].
    Quaranta M; Micelli G; Coviello M; Donadeo A; Lozupone A; Schittulli F
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):35-8. PubMed ID: 2092146
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pre- and post-therapeutic serum concentrations of mucin-like carcinoma-associated antigen in patients with breast cancer].
    Fuith LC; Artner-Dworzak E; Schröcksnadel H; Müller-Holzner E; Daxenbichler G; Heim K
    Gynakol Rundsch; 1989; 29 Suppl 2():397-9. PubMed ID: 2613061
    [No Abstract]   [Full Text] [Related]  

  • 5. [Tumor markers in metastatic breast carcinoma: correlations with clinical response].
    Winer Y; Martini MC; Pastorino G; Moraglio L; Vallauri M; Brondi P; Brema F
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):127-30. PubMed ID: 2092107
    [No Abstract]   [Full Text] [Related]  

  • 6. [Determination of MCA, CA 15.3, CA M26, in carcinoma of the breast].
    Bumma C; Bramardi AM; Lauria G; Arese P; Marchetti G
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):29-32. PubMed ID: 2092137
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of the BT-1 serum assay for breast cancer.
    Whitehurst MM; Aldenderfer PH; Sooy MM; Strelkauskas AJ
    Hum Antibodies; 1999; 9(3):155-60. PubMed ID: 10690628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preliminary experience with BCM-IMx as a pretreatment marker of breast tumors].
    Fernández Llana B; Fernández Fernández M; Suárez B; Allende MT
    Rev Clin Esp; 1992 Mar; 190(4):209. PubMed ID: 1589619
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of MCA and CA 15-3 in tissue and in serum of patients with breast carcinoma: preliminary results.
    Reale G; Giovagnoli MR; Vecchione A; Cosentino L; Benci F; Manna A; Marchei G; Vittori I; Frati L
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):53. PubMed ID: 2092150
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M; Tikanoja S; Brown J
    Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
    Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements.
    Jäger W
    Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():133-9. PubMed ID: 8298443
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
    Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
    Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor associated glycoprotein (TAG) 12: a new tumor marker in breast cancer.
    Heinze T; Lichtenegger W
    Anticancer Res; 2000; 20(6D):5049-52. PubMed ID: 11326666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA 549 (hybriBREScan) in breast cancer.
    Cooper EH; Laurence V; Hancock AK; Parker D; Forbes MA
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):39-41. PubMed ID: 2092147
    [No Abstract]   [Full Text] [Related]  

  • 17. Circulating tumor markers in breast cancer.
    Tondini C; Hayes DF; Kufe DW
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):653-74. PubMed ID: 2691493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of present tumor markers].
    Ohkura H
    Gan To Kagaku Ryoho; 1993 May; 20(7):843-9. PubMed ID: 7683865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serological tumor markers for monitoring breast cancer.
    Sölétormos G
    Dan Med Bull; 2001 Nov; 48(4):229-55. PubMed ID: 11767127
    [No Abstract]   [Full Text] [Related]  

  • 20. [NCC-ST-439].
    Sugano K
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():681-3. PubMed ID: 16149610
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.